var data={"title":"Pancuronium: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pancuronium: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6720?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pancuronium-drug-information\" class=\"drug drug_general\">see &quot;Pancuronium: Drug information&quot;</a> and <a href=\"topic.htm?path=pancuronium-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pancuronium: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709194\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced personnel:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">This drug should be administered by adequately trained individuals familiar with its actions, characteristics, and hazards.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2980447\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pancuronium Bromide&reg;</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060895\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Neuromuscular Blocker Agent, Nondepolarizing</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Skeletal Muscle Relaxant, Paralytic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444088\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Paralysis/skeletal muscle relaxation:</b> IV: 0.05 to 0.1 mg/kg/dose (Costarino 1987; Kumar 2010); may repeat dose every 1 to 2 hours as needed  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060888\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pancuronium-drug-information\" class=\"drug drug_general\">see &quot;Pancuronium: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing in obese patients should be calculated using ideal body weight (Playfor 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Paralysis/skeletal muscle relaxation:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent dosing: 0.05 to 0.1 mg/kg/dose as needed (usually every 4 to 6 hours) (Martin 1999; Playfor 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: 0.4 to 0.6 <b>mcg</b>/kg/minute (0.02 to 0.04 mg/kg/<b>hour</b>) (Martin 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent IV: 0.05 to 0.15 mg/kg/dose as needed (usually every 4 to 6 hours)  (Martin 1999; Playfor 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: 0.5 to 1 <b>mcg</b>/kg/minute (0.03 to 0.06 mg/kg/<b>hour</b>) (Martin 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermittent IV: 0.05 to 0.15 mg/kg/dose as needed (usually every 4 to 6 hours) (Martin 1999; Playfor 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: 0.4 to 0.6 <b>mcg</b>/kg/minute (0.02 to 0.04 mg/kg/<b>hour</b>) (Martin 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Dose to effect; doses will vary due to interpatient variability; use ideal body weight for obese patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgery:</b> IV: Initial: 0.06 to 0.1 mg/kg or 0.05 mg/kg after initial dose of succinylcholine for intubation; maintenance dose: 0.01 mg/kg administered 60 to 100 minutes after initial dose and then 0.01 mg/kg every 25 to 60 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>ICU paralysis (eg, facilitate mechanical ventilation) in select adequately sedated patients:</b> IV: 0.06 to 0.1 mg/kg bolus followed by either:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: 1 to 2 <b>mcg</b>/kg/minute (0.06 to 0.12 mg/kg/<b>hour</b>) (Murray 2002) or 0.8 to 1.7 <b>mcg</b>/kg/minute (0.048 to 0.102 mg/kg/<b>hour</b>) (Greenberg 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent bolus: 0.1 to 0.2 mg/kg every 1 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Elimination half-life is doubled, plasma clearance is reduced and rate of recovery is sometimes much slower. There are no dosage adjustments provided in manufacturer&rsquo;s labeling; however, the following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: <b>Note:</b> Renally adjusted dose recommendations are based on doses of 0.1 to 0.2 mg/kg/dose every 2 to 4 hours or 0.5 to 1 mcg/kg/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 50% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): Administer 50% of normal dose; titrate to effect.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 10 to 50 mL/minute: Administer 50% of normal dose. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;10 mL/minute: Avoid use. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis/peritoneal dialysis: Avoid use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CRRT: Administer 50% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults: Elimination half-life is doubled, plasma clearance is doubled, recovery time is prolonged, volume of distribution is increased (50%) and results in a slower onset, higher total dosage, and prolongation of neuromuscular blockade. Patients with liver disease may develop slow resistance to nondepolarizing muscle relaxant. Large doses may be required and problems may arise in antagonism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206121\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as bromide: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (10 mL); 2 mg/mL (2 mL [DSC], 5 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206107\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060898\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV push: Administer undiluted by rapid IV injection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV Infusion: Further dilute in an appropriate fluid and administer via an infusion pump </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206136\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Refrigerate; however, stable for up to 6 months at room temperature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060897\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunct to anesthesia, to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206191\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">United States Pharmacopeia (USP) 2006: The Interdisciplinary Safe Medication Use Expert Committee of the USP has recommended the following:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">- Hospitals, clinics, and other practice sites should institute special safeguards in the storage, labeling, and use of these agents and should include these safeguards in staff orientation and competency training.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">- Healthcare professionals should be on high alert (especially vigilant) whenever a neuromuscular-blocking agent (NMBA) is stocked, ordered, prepared, or administered.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206188\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, increased blood pressure, increased cardiac work, increased pulse, severe myasthenia (long-term use)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Paralysis (long-term use)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Sialorrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylactoid reaction, anaphylaxis, bronchospasm, erythema, hypersensitivity reaction, hypotension, tachycardia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206127\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pancuronium, bromide, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206111\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Burn injury: Resistance may occur in burn patients (&ge;20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han, 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conditions which may <i>antagonize</i> neuromuscular blockade: Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, and muscle trauma may result in antagonism of neuromuscular blockade (Greenberg, 2013; Miller, 2010; Murray, 2002; Naguib, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Conditions which may <i>potentiate</i> neuromuscular blockade: Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), neuromuscular diseases, metabolic acidosis, metabolic alkalosis, respiratory acidosis, Eaton-Lambert syndrome and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg, 2013; Miller, 2010; Naguib, 2002). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Elimination half-life is doubled due to reduced clearance of pancuronium and recovery is prolonged; use with caution in patients with hepatic impairment and adjust dose appropriately. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Elimination half-life is doubled due to reduced clearance of pancuronium and recovery is prolonged; use with caution in patients with renal impairment and adjust dose appropriately. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly, effects and duration are more variable.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Immobilized patients: Resistance may occur in patients who are immobilized.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Maintenance of an adequate airway and respiratory support is critical. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced personnel: <b>[U.S. Boxed Warning]: Should be administered by adequately trained individuals familiar with its use.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299816\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206115\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12676&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Neuromuscular-Blocking Agents may diminish the therapeutic effect of Amifampridine. Amifampridine may diminish the therapeutic effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Neuromuscular-Blocking Agents (Nondepolarizing) may enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents (Nondepolarizing). Specifically, episodes of apnea have been reported in patients using this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<b> Exceptions: </b>Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Neuromuscular-Blocking Agents may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: May enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium. Management: Pancuronium dosage adjustment may be necessary to induce paralysis  in patients receiving concomitant theophylline derivatives. Monitor closely for adverse effects (e.g., cardiac effects) with concomitant use of these agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimebutine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206117\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13494861\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Small amounts of pancuronium cross the placenta (Daily, 1984). May be used short-term in cesarean section; reduced doses recommended in patients also receiving magnesium sulfate due to enhanced effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060894\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure, assisted ventilation status, peripheral nerve stimulator measuring twitch response</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206110\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F206126\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of effect (Martin 1999): Infants: 2 to 5 minutes; Children: 2 to 4 minutes; Adults: 3 to 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration (dose dependent): Children: 24 minutes; Adults: 22 minutes (Martin 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.24 to 0.28 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 87%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (30% to 45%); active metabolite 3-hydroxypancuronium (<sup>1</sup>/<sub>3</sub> to <sup>1</sup>/<sub>2</sub> the activity of parent drug)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 89 to 161 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (40%); bile (11%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323611\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Pancuronium Bromide Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (10 mL): $5.69</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038717\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alpax (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Bromurex (CO);</li>\n      <li>Curon-B (ZA);</li>\n      <li>Maoblock (KR);</li>\n      <li>Neocuron (ET, LK);</li>\n      <li>Panalon (BD);</li>\n      <li>Panconium (IN);</li>\n      <li>Pancuron (BR, PY);</li>\n      <li>Pancuronio (CO);</li>\n      <li>Pancuronium (PL);</li>\n      <li>Pancuronium Bromide (AU);</li>\n      <li>Pavulon (AE, AT, AU, BD, BE, BG, BH, CH, CN, CY, CZ, DE, DK, EE, EG, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IN, IQ, IR, IT, JO, JP, KW, LB, LU, LY, MT, MY, NL, NO, OM, PH, PK, PL, PT, QA, RU, SA, SE, SG, SI, SK, SY, TH, TR, TW, VE, VN, YE);</li>\n      <li>Pavulone (IL);</li>\n      <li>Unacron (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancuronium-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancuronium-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancuronium-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costarino AT, Polin RA. Neuromuscular relaxants in the neonate. <i>Clin Perinatol</i>. 1987;14(4):965-989. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancuronium-pediatric-drug-information/abstract-text/2827933 /pubmed\" target=\"_blank\" id=\"2827933 \">2827933 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dailey PA, Fisher DM, Shnider SM, et al. Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. <i>Anesthesiology</i>. 1984;60(6):569-574. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancuronium-pediatric-drug-information/abstract-text/6145374/pubmed\" target=\"_blank\" id=\"6145374\">6145374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenberg SB and Vender J, &ldquo;The Use of Neuromuscular Blocking Agents in the ICU: Where Are We Now?&rdquo; <i>Crit Care Med</i>, 2013, 41(5):1332-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancuronium-pediatric-drug-information/abstract-text/23591211/pubmed\" target=\"_blank\" id=\"23591211\">23591211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Han TH, Martyn JAJ. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus. <i>Br J Anaesth</i>. 2009;102(1):55-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancuronium-pediatric-drug-information/abstract-text/19029093/pubmed\" target=\"_blank\" id=\"19029093\">19029093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar P, Denson SE, Mancuso TJ, et al, &quot;Premedication for Nonemergency Endotracheal Intubation in the Neonate,&quot; <i>Pediatrics</i>, 2010, 125(3):608-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancuronium-pediatric-drug-information/abstract-text/20176672/pubmed\" target=\"_blank\" id=\"20176672\">20176672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin LD, Bratton SL, and O'Rourke PP, &ldquo;Clinical Uses and Controversies of Neuromuscular Blocking Agents in Infants and Children,&rdquo; <i>Crit Care Med</i>, 1999, 27(7):1358-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancuronium-pediatric-drug-information/abstract-text/10446832/pubmed\" target=\"_blank\" id=\"10446832\">10446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray MJ, Cowen J, DeBlock H, et al, &ldquo;Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians,&rdquo; <i>Crit Care Med</i>, 2002, 30(1):142-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancuronium-pediatric-drug-information/abstract-text/11902255/pubmed\" target=\"_blank\" id=\"11902255\">11902255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pancuronium injection [prescribing information]. Lake Forest, IL: Hospira, Inc; September 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Playfor S, Jenkins I, Boyles C, et al. Consensus guidelines for sustained neuromuscular blockade in critically ill children. <i>Paediatr Anaesth</i>. 2007;17(9):881-887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pancuronium-pediatric-drug-information/abstract-text/17683408 /pubmed\" target=\"_blank\" id=\"17683408 \">17683408 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Oder Entry System. <i>Hosp Pharm</i>. 2006;41(11):1102-1106. Erratum in: <i>Hosp Pharm</i>. 2007;42:84-85.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12676 Version 102.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709194\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F2980447\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060895\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444088\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060888\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F206121\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F206107\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060898\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F206136\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060897\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F206191\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F206188\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F206127\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F206111\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299816\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F206115\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F206117\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13494861\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1060894\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F206110\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F206126\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323611\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038717\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12676|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pancuronium-drug-information\" class=\"drug drug_general\">Pancuronium: Drug information</a></li><li><a href=\"topic.htm?path=pancuronium-patient-drug-information\" class=\"drug drug_patient\">Pancuronium: Patient drug information</a></li></ul></div></div>","javascript":null}